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RESEARCH ARTICLE Open Access
Stress granules and RNA processing bodies
are novel autoantibody targets in systemic
sclerosis
Michael E. Johnson1, Andrew V. Grassetti1, Jaclyn N. Taroni1, Shawn M. Lyons2, Devin Schweppe1, Jessica K. Gordon3,
Robert F. Spiera3, Robert Lafyatis4, Paul J. Anderson2, Scott A. Gerber1 and Michael L. Whitfield1,5*
Abstract
Background: Autoantibody profiles represent important patient stratification markers in systemic sclerosis (SSc).
Here, we performed serum-immunoprecipitations with patient antibodies followed by mass spectrometry (LC-MS/MS)
to obtain an unbiased view of all possible autoantibody targets and their associated molecular complexes recognized
by SSc.
Methods: HeLa whole cell lysates were immunoprecipitated (IP) using sera of patients with SSc clinically positive
for autoantibodies against RNA polymerase III (RNAP3), topoisomerase 1 (TOP1), and centromere proteins (CENP). IP
eluates were then analyzed by LC-MS/MS to identify novel proteins and complexes targeted in SSc. Target proteins
were examined using a functional interaction network to identify major macromolecular complexes, with direct targets
validated by IP-Western blots and immunofluorescence.
Results: A wide range of peptides were detected across patients in each clinical autoantibody group. Each group
contained peptides representing a broad spectrum of proteins in large macromolecular complexes, with significant
overlap between groups. Network analyses revealed significant enrichment for proteins in RNA processing bodies
(PB) and cytosolic stress granules (SG) across all SSc subtypes, which were confirmed by both Western blot and
immunofluorescence.
Conclusions: While strong reactivity was observed against major SSc autoantigens, such as RNAP3 and TOP1, there
was overlap between groups with widespread reactivity seen against multiple proteins. Identification of PB and SG as
major targets of the humoral immune response represents a novel SSc autoantigen and suggests a model in which a
combination of chronic and acute cellular stresses result in aberrant cell death, leading to autoantibody generation
directed against macromolecular nucleic acid-protein complexes.
Keywords: Systemic sclerosis, Scleroderma, Autoantibody, RNA processing bodies, Stress granules
Background
Systemic sclerosis (SSc) is a rare systemic autoimmune
disease of unknown etiology characterized by skin
fibrosis, internal organ involvement, vascular abnor-
malities, and autoantibody production. Patients are
broadly classified as having either limited (lSSc) or dif-
fuse (dSSc) disease based primarily upon the extent of
skin involvement and autoantibody profiles. While a
wide array of autoantibodies have been described for
SSc, only a small number of these targets are used for
clinical diagnosis and stratification. Autoantibodies
targeting RNA polymerase III (RNAP3), topoisomer-
ase 1 (TOP1; commonly referred to as Scl70), and
centromere proteins (CENP) represent the three the
most common, clinically measured autoantibodies ob-
served in SSc [1, 2]. Other autoantibodies, including
fibrillarin (U3RNP), Pm/Scl, Ku, U1RNP, U11/U12,
and Th/To have also been described [1, 3] but are not
routinely measured for clinical subtyping.
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While the processes underlying autoantibody produc-
tion in SSc remain poorly understood, the presence of
certain autoantibodies is strongly predictive of clinical
outcomes [1–3]. TOP1 and RNAP3 autoantibodies are
almost exclusively seen in dSSc, while CENP, Th/To, and
U1RNP antibodies are more commonly associated with
lSSc [1, 3]. U3RNP autoantibodies are not associated
with either clinical subset, and are often found in con-
junction with other autoantibodies, including both
TOP1 and CENP [3]. Certain antibodies, such as TOP1
and U11/12, have been shown to be predictive of poorer
overall prognosis, including increased likelihood of pul-
monary fibrosis [4] and cardiac involvement, while
RNAP3 autoantibodies have recently been linked to co-
occurrence of SSc with cancer [5].
Despite the importance of autoantibodies in SSc, the
vast majority of target identification and phenotypic
screening has been performed using methods targeting
only a single autoantibody, with little ability to detect
novel or low abundance autoantibodies. Furthermore,
these methods fail to address the possibility of co-
occurrence of multiple autoantibodies within a patient,
which may have important clinical implications. Autoan-
tigen microarrays have proven successful for screening
large numbers of autoantibodies in parallel, however tar-
get identification is limited to those antigens produced
and printed on the antigen microarrays [6]. To address
these limitations, we performed immunoprecipitations
(IP) of HeLa whole cell lysates using sera from RNAP3-,
CENP-, and TOP1-positive patients, as well as healthy
controls, followed by mass spectrometry (LC-MS/MS) to
provide an unbiased assessment of all autoantibodies
present in these SSc patients. This method provides a
better view of the full range of autoantibodies present in
SSc, including both novel and established targets, and
provides insights into the general processes underlying
autoantibody production.
Methods
Clinical samples
Patient serum was obtained from Boston University
Medical School, Boston (BUMC), MA, USA and the
Hospital for Special Surgery (HSS), New York, NY,
USA. All relevant study protocols were approved by
the Dartmouth College committee for the protection
of human subjects, and the internal review boards of
both BUMC and HSS. Informed consent was ob-
tained from all patients prior to sample collection.
Patients were diagnosed with either dSSc or limited
SSc, as determined using the 1980 American College
of Rheumatology classification criteria. Detection of
major autoantibody reactivities was performed using
standard clinical assays.
Human cell lysates
HeLa cells were cultured in DMEM supplemented with
10 % fetal bovine serum (FBS) (v/v) and 100 IU/mL
penicillin-streptomycin. Cells were grown to approxi-
mately 80 % confluence, harvested in IP lysis buffer
(150 mM NaCl, 50 mM Tris pH 7.5, 1 mM MgCl2, 1 mM
EDTA, 0.5 % Triton X-100, 2.5 mM β-mercaptoethanol,
1 mM sodium molybdate, 1 mM sodium fluoride, 1 mM
sodium tartrate, 1 mM dithiothreitol (DTT), and protease
inhibitors (Roche, Indianapolis, IN, USA)), lysed by pas-
sage through a pre-chilled high-gauge syringe, and centri-
fuged for 15 minutes to pellet debris. Lysates were then
clarified by incubating for 4 h at 4 °C on a rotating plat-
form. Protein concentrations were quantified using a
standard bicinchoninic acid (BCA) protein assay kit
(Thermo Scientific, Waltham, MA, USA).
Serum immunoprecipitation
Patient serum was cross-linked to Protein G Dynabeads
(Invitrogen, St. Louis, MO, USA) prior to IP. First,
100 μL serum (approximately 1 mg IgG) was added to
50 μL Protein G beads and incubated for 5 h at 4 °C.
Samples were then washed in PBS, equilibrated in cross-
linking buffer (50 mM HEPES, pH 8.2), and cross-linked
to Protein G beads by the addition of 20 mM dimethyl
pimelimidate and 300 mM HEPES (DMP) solution for
10 minutes at room temperature (repeated three times).
The crosslinking reaction was then terminated by the
addition of 50 mM ammonium bicarbonate, and the
resulting antibody bead mixture added to 500 μL cell
lysate (diluted to 4 mg/mL in IP lysis buffer). Samples
were incubated overnight at 4 °C on a rotating platform,
washed in cold IP lysis buffer, and eluted in a buffer con-
taining 2 % SDS, 75 mM NaCl, 50 mM Tris pH 8.1, and
20 % glycerol at 65 °C for 5 minutes. Eluates were re-
duced by the addition of 0.1 M dithiothreitol (DTT) (to
a final concentration 5 mM), and incubated at 80 °C for
5 minutes. Samples were then resolved by SDS-PAGE,
split into high (>60 kDa) and low (<60 kDa) molecular
weight fractions and analyzed by mass spectrometry.
Mass spectrometry
Proteins contained in Coomassie-stained gel regions
were digested overnight with trypsin (1:200 w/v) at 37 °
C. Following digestion, peptides were extracted from the
gels, dried, and analyzed by nanoscale LC-MS/MS. LC-
MS/MS analyses were performed on either LTQ Orbi-
trap Classic or Orbitrap Fusion LC-MS/MS platforms.
LTQ Orbitrap Classic analyses were conducted as de-
scribed previously [7].
For Orbitrap Fusion analyses, samples were loaded onto
an EASY-nLC 1000 Liquid Chromatograph (Thermo Sci-
entific, Waltham, MA, USA) and separated by reverse-
phase high pressure liquid chromatography (RP-HPLC)
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using an approximately 36-cm column with a 100-μM
inner diameter packed with 3 μm 120 Å C18 particles (Dr.
Maisch GmbH, Ammerbuch-Entringen, Germany). The
resultant peptide eluate was directed into an Orbitrap
Fusion Tribrid Mass Spectrometer operating in a data-
dependent sequencing acquisition mode across a 30-
minute reverse-phase gradient (6 % acetonitrile, 0.1 %
formic acid to 30 % acetonitrile, 0.1 % formic acid) at
350 nL/min flow rate. The Orbitrap Fusion was operated
with an Orbitrap MS1 scan at 120 K resolution, followed
by Orbitrap MS2 scans of higher energy collision-induced
dissociation (HCD) fragment ions (30 % HCD energy) at
15 K resolution using a maximum cycle type of 2 s,
precursor ion dynamic exclusion window of 15 s, +2, +3,
and +4 precursor ions selected for LC-MS/MS, and max-
imum ion injection times of 100 ms (MS1) and 50 ms
(MS2). The resulting tandem mass spectra were data-
searched using the COMET search engine [8] against a
Homo sapiens proteome database (source: Uniprot;
download date: 2 July 2013) with a precursor ion tol-
erance of +/- 1 Da [9] and a fragment ion tolerance
of 0.02 Th. Peptide spectra matches (PSMs) were fil-
tered to <1 % false discovery rate using the target
decoy strategy [10], and reported.
IP-western blots
Anti-UPF1 antibody was kindly provided by Dr. Lynne
Maquat (University of Rochester Medical Center, Roch-
ester, NY, USA). Antibodies to MOV10 and CAPRIN1
were purchased from Proteintech (Chicago, IL, USA);
antibodies to G3BP1 and USP10 were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Serum immunoprecipitation of HeLa lysates was per-
formed as described above; 50 % of each eluate (15 μL)
was then run on a 10 % bis-tris precast gel (Life Tech-
nologies, Carlsbad, CA, USA). HeLa whole cell lysate
(100 μg) was used as a positive control; no loading con-
trol was performed due to the absence of viable targets
present in all IP eluates. Western blots were then run
following standard protocols, and visualized using West-
ern Lightning ECL Pro or Ultra substrate (Perkin Elmer
Inc., Waltham, MA, USA), as necessary.
Data analysis
Non-redundant peptide hits, defined as mass spectra
mapping exclusively to a given peptide fragment, were
used for all downstream analyses. Pairwise comparisons
between samples were performed by Fisher’s exact test
using the Bonferroni correction for multiple hypothesis
testing. Venn diagrams were generated using VENNY
[11]. Network analysis was performed using the Genome-
scale Integrated Analysis of gene Networks in Tissues
(GIANT; http://giant.princeton.edu/) global network [12]
and visualized using Cytoscape [13]. Communities in the
network were detected using fast-greedy modularity as
implemented in igraph. Functional annotation of individ-
ual communities was performed using g:Profiler [14].
Semiquantitative enrichment of SSc-associated autoanti-
bodies was determined using a binary assessment of auto-
antibody presence or absence in a sample. Preferential
enrichment in SSc was defined as all proteins de-
tected in >50 % of all patient samples at a frequency >1.5-
fold relative to controls. Enrichment of biological processes
and cellular components was determined using g:Profiler
using the g:SCS threshold correction for multiple hypoth-
esis testing and a functional category size ≤500 genes.
Hierarchical clustering was performed using Cluster 3.0
[15], and visualized using Java TreeView [16].
Immunofluorescence
The day prior to the experiment, 105 U2OS cells were
seeded onto 11 mm glass coverslips and allowed to at-
tach overnight at 37 °C/5 % CO2 in DMEM containing
10 % FBS (Gibco). Cells were treated with 100 μM so-
dium (meta)arsenite (Sigma Aldrich) for 1 h to induce
the formation of stress granules and then with 4 % para-
formaldehyde solution at room temperature for 15 -
minutes followed by blocking and permeabilization with
5 % normal horse serum, 0.1 % digitonin in Tris-
buffered saline. Staining was performed with anti-eIF3b
(Santa Cruz), anti-SK1-Hedls (Santa Cruz), and patient
sera for 1 h at room temperature. Secondary antibodies
(anti-goat-Cy3, anti-mouse-Cy2, and anti-human-Cy5)
were purchased from Jackson Laboratories and incubated
at room temperature for 1 h. Conventional fluorescence
microscopy was performed using a microscope (model
Elipse E800, Nikon, Tokyo, Japan) with epifluorescence
optics with a digital camera (model CCD-SPOT RT; Diag-
nostic Instruments, Sterling Heights, MI). Images were
compiled using Adobe Photoshop software (CS6; Adobe
Systems, San Jose, CA).
Results
Identification of proteins cross-reacting to serum antibodies
Immunoprecipitations (IP) of HeLa whole cell lysates
were performed using sera obtained from 13 SSc pa-
tients and 4 healthy controls. HeLa cells were chosen
based upon their consistent, high level of expression of a
broad range of proteins from the human genome [17].
SSc patients were divided into three groups, TOP1,
RNAP3, and CENP, as measured in a reference labora-
tory; clinical data for each patient are shown in Table 1.
These groups were chosen based upon their relative
frequency, and their importance in clinical diagnosis.
Immunoprecipitated proteins were analyzed by LC-MS/
MS, and the resulting spectra aligned to the reference
human proteome (UCSC version hg19). Data are pre-
sented in two ways; first to identify the total number of
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peptides that could be aligned to each protein (total
hits), and second to identify all non-redundant peptides
that mapped exclusively to a given protein (non-redun-
dant hits). A complete list of all data can be found in
Additional file 1: Table S1.
Exclusivity and co-occurrence of SSc autoantibodies
We observed a high degree of reproducibility between
patients within their respective autoantibody groups
(TOP1, RNAP3, and CENP; Fig. 1). The greatest degree of
overlap between peptides was observed among RNAP3
patients (Fig. 1a and c), with 420 proteins (54.1 %) de-
tected in all four patients (Fig. 1c). The remaining groups
exhibited significant overlap in three of four (TOP1) and
four of five (CENP) patients, respectively (Fig. 1a), along
with a single outlier that showed either higher (SSc 208;
TOP1) or lower (SSc 226; CENP) total peptide hits relative
to other samples in these groups. Within TOP1, 111 pro-
teins (14.2 %) were detected in all four patients (Fig. 1d),
while CENP exhibited 48 proteins (10.5 %) common to all
patients (Fig. 1c). The least overlap was seen in healthy
controls, with only 40 proteins (7.6 %; Fig. 1b) common
across individuals.
Across all samples, 283 proteins (25.0 %) were de-
tected in at least one patient in each of the four auto-
antibody groups (Fig. 1e, Additional file 2: Table S2).
Some of these proteins likely represent background
signals (serum albumin (ALB), β-tubulin (TUBB), and
ribosomal proteins), while others are considered specific
to SSc despite trace level detection in controls. For ex-
ample, multiple SSc autoantibody targets, including Ku
(XRCC5 and XRCC6), Ro52/TRIM21, and nucleophos-
min/B23 (NPM1) were present in this set of proteins. In
contrast, 87 proteins (7.7 %) were detected in all three
SSc groups, but were absent in controls (Fig. 1e;
Additional file 2: Table S2). Functional analyses of these
proteins revealed strong enrichment of proteins involved
in oxidative stress responses and nucleic acid processing
(Additional file 3: Table S3B).
Of the 1,130 non-redundant proteins identified, 473
(41.8 %) were unique to a given autoantibody group
(Fig. 1f ); however, the vast majority of these proteins
were exclusive to a single patient, with only 111 (23.5 %)
detected in two or more patients. These results suggest a
wide range of autoantibody responses within each of the
clinical autoantibody groups beyond what has already
been described.
Among the major autoantibody groups, immunopre-
cipitation of RNAP3 was exclusive to the RNAP3 group,
with no RNAP3 peptides detected in any of the other
samples (Table 2). In contrast, TOP1 peptides were
consistently highest among TOP1 patients, but were also
detected at low levels in all four RNAP3+ patients, and
in two controls (Table 2). As these patients were
negative for TOP1 autoantibodies by clinical testing,
these results indicate a higher degree of sensitivity for
our IP/MS protocol compared to standard ELISA-based
methods used clinically. In contrast, CENP was only
Table 1 Clinical information for patients involved in this study
Sample Group Age (years) Sex Race Disease type ILD/PAH Disease duration (years) ANA pattern ANA titer MRSS
SSc 1 TOP1 36 F White Diffuse mild ILD 2.5 1:320 43
SSc 132 TOP1 49 F White Diffuse No Homogeneous 1:640 27
SSc 218 TOP1 55 F White Diffuse ILD Homogeneous/nucleolar 1:2560 18
SSc 208 TOP1 64 M White Diffuse No Nucleolar 1:1280 37
SSc 5 RNAP3 53 M White Diffuse No 0.75 Speckled 1:80 36
SSc 7 RNAP3 45 F Black Diffuse No 0.5 Speckled 1:80 27
SSc 10 RNAP3 52 M White Diffuse No 0.5 0 22
SSc 18 RNAP3 69 F White Diffuse ILD 0.5 Nucleolar 1:160 44
SSc 159 CENP 54 F Mixed Limited No 7 Centromere 1:1280 2
SSc 177 CENP 64 F White Limited No 15 Discrete speckled 4+
SSc 194 CENP 66 F White Limited No 18 Discrete speckled 4+ 6
SSc 238 CENP 53 F White Limited No 6 Centromere 1:640 5
SSc 226 CENP 55 F Asian Diffuse No Centromere 1:1280 6
HC 162 Control 24 M White
HC 400 Control 21 M White
HC 117 Control M
HC 118 Control M
Blank cells indicate information not available at the time of sample collection. ILD interstitial lung disease, PAH pulmonary arterial hypertension, ANA anti-nuclear
antibody, MRSS modified Rodnan skin score, SSc systemic sclerosis, M male, F female
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detected at low levels in the CENP group, likely because
it remained bound to the tightly packed centromere
complex of chromatin.
Other known SSc autoantigens were also detected.
RuvBL [18] was strongly detected in all SSc samples, while
virtually absent in controls. Ku and Su, along with a wide
array of anti-tRNA synthetases [19] were routinely detected
in both the RNAP3 and TOP1 subsets, but were only
weakly present in the CENP and control groups (Table 2).
Several autoantigens previously implicated in SSc were
found at low, background levels in both SSc and control
samples. Ro52/TRIM21 [20] and nucleophosmin/B23
[21] were widely detected across all four groups, suggest-
ing widespread reactivity to these proteins in SSc and
controls. We did not find evidence in SSc of enrichment
of Pm/Scl autoantibodies, which target exosome compo-
nents EXOSC1-10 [22]. Peptides for these proteins were
absent in the CENP group, but were detected at low
levels in other subsets, including controls. Autoantigens
not detected here include many of the URNPs, PDGFR,
matrix metalloproteinases, tissue plasminogen activator,
and vascular receptor antibodies (Table 2).
Functional clustering of identified proteins
To identify functional interactions among autoantigens,
all 763 non-redundant protein hits were submitted as a
query to the GIANT global average network. This ap-
proach included both SSc-specific targets and those de-
tected at background levels in controls, to better
understand the full range of autoreactive proteins and
complexes. Nine distinct communities were identified
within the resulting network, in which each gene is rep-
resented by a node, and two genes share an edge if they
are predicted to functionally interact (Additional file 4:
Figure S1). Analysis of each of these communities by
g:Profiler revealed functional enrichment for a wide
range of biological processes associated with important
disease processes and components (Additional file 4:
Figure S1). Community 1 is dominated by ribosomal
proteins, eukaryotic initiation factor 3 (eIF3) subunits,
and includes the SSc autoantibody target nucleophos-
min/B23. Communities 2 and 8 show strong enrichment
for Gene Ontology (GO) terms mRNA processing, ribo-
nucleoprotein complex, and cytosolic stress granule.
Community 2 is dominated primarily by DEAD box
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Table 2 SSc-associated autoantibodies observed in this study
Alias Associated proteins Disease subset Clinical associations Prevalence in this dataset (avg/freq) Reference
Control (n = 4) RNAP3 (n = 4) TOP1 (n = 4) CENP (n = 5)
Major autoantibodies
RNA Pol III POLR3A dSSc Renal crisis, cancer - +++ (28/4) - - Graf, et al. 2012 [1]; Mehra,
et al. 2013 [3]
Scl70 TOP1 dSSc Poor prognosis, internal organ
involvement, and proteinuria
+ (3/2) + (4/4) +++ (19/4) - Mehra, et al. 2013 [3]
Centromere CENPB, CENPH lSSc/CREST PAH, ILD - - - + (1/2) Mehra, et al. 2013 [3]
Other SSc autoantibodies present in our dataset
Endothelial Cell TUBB, VCL, LMNA, RPLP0 SSc PAH + (1/1) ++ (6/4) + (4/2) + (0/1) Dib, et al. 2012 [34], Naniwa,
et al. 2007 [35]
Fibroblast ENO1, G6PD, HSPA1A,
HSPA1B, VIM
SSc PAH + (3/4) +++ (12/4) ++ (5/3) ++ (8/5) Terrier, et al. 2008 [36],
Terrier, et al. 2009 [37]
Histone H1FX, HIST1H1B, HIST1H4A SSc PF, internal organ involvement,
decreased survival
+ (1/1) + (3/3) + (1/1) - Mehra, et al. 2013 [3]
B23 NPM1 dSSc, CENP- lSSc PAH + (4/4) ++ (7/4) ++ (5/4) ++ (6/5) Mehra, et al. 2013 [3]
Ku XRCC5, XRCC6 lSSc Myositis + (3/3) +++ (12/4) ++ (8/4) + (2/3) Graf, et al. 2012 [1]; Mehra,
et al. 2013 [3]
Su AGO2 SSc, PM/Scl Unknown - + (1/2) + (3/1) - Satoh, et al. 2013 [38]
Mitochondrial (M2) DLD, PDHB lSSc Strong association with primary
biliary cirrhosis
+ (1/1) + (2/3) + (1/1) - Mehra, et al. 2013 [13]
Pm/Scl EXOSC1-10 SSc PF, digital ulcers; decreased risk
of PAH and GI symptoms
+ (2/2) ++ (5/3) + (2/2) - Mehra, et al. 2013 [13]
hnRNPs HNRNPA1-3, HNRNPL SSc Common in SARDs + (0/1) ++ (7/4) + (3/4) + (2/4) Siapka, et al. 2007 [39]
U1 SNRNPA, SPRNP70 SSc Co-occurrence with SS-A/SS-B,
PAH, overlap syndrome
- + (2/4) + (1/2) + (0/1) Graf, et al. 2012 [1]; Mehra,
et al. 2013 [3]
U5 SNRNP200 SSc, PM/Scl Unknown ++ (6/3) ++ (9/4) ++ (8/3) + (1/2) Kubo, et al. 2002 [40]
RO52/TRIM21 TRIM21 SSc ILD, other autoimmune diseases ++ (6/3) +++ (12/4) ++ (6/4) ++ (8/4) Mehra, et al. 2013 [3]
RuvB RUVBL1, RUVBL2 dSSc Common in SARDs, older age at
onset, male sex
+ (1/1) ++ (7/4) + (3/4) + (2/4) Kaji, et al. 2014 [18]
Annexin V ANXA5 dSSc, CENP- lSSc Digital ischemia + (2/2) ++ (7/4) + (4/3) + (3/4) Mehra, et al. 2013 [3]
SS-B/LA SS-A, SS-B SSc ILD, other autoimmune diseases - + (3/4) + (2/2) + (0/1) Mehra, et al. 2013 [3]
Peroxiredoxin PRDX1 SSc Disease duration, PF, cardiac
involvement, TOP1+ patients
+ (2/4) ++ (8/4) + (3/3) + (4/4) Mehra, et al. 2013 [3]
hUBF/NOP90 UBTF lSSc Mild organ involvement,
favorable prognosis
- + (1/2) - - Mehra, et al. 2013 [3]
Th/To POP1 lSSc PF, renal crisis, poor prognosis,
myositis, PAH
+ (1/2) + (1/1) + (3/3) - Graf, et al. 2012 [1]; Mehra,
et al. 2013 [3]
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Table 2 SSc-associated autoantibodies observed in this study (Continued)
PL-12 AARS SSc, PM/DM ILD without myositis - - + (1/1) + (1/1) Hamaguchi, et al. 2013 [19]
OJ IARS SSc, PM/DM ILD without myositis + (1/1) - + (3/3) - Hamaguchi, et al. 2013 [19]
EJ GARS SSc, PM/DM ILD, myositis - + (3/4) + (2/2) + (0/1) Hamaguchi, et al. 2013 [19]
Jo-1 HARS SSc, PM/DM ILD, myositis - + (1/4) - - Hamaguchi, et al. 2013 [19]
PL-7 TARS SSc, PM/DM ILD, myositis + (2/2) ++ (8/4) ++ (6/4) + (2/4) Hamaguchi, et al. 2013 [19]
Ha YARS SSc, PM/DM Interstitial pneumonia - + (0/1) - - Hashish, et al 2005 [41]
Zo FARSA, FARSB SSc, PM/Scl Anti-synthetase syndrome - + (2/4) - - Betteridge, et al. 2007 [42]
SSc autoantibodies not detected in our dataset
Fibrillarin U3RNP dSSc More frequent in blacks; severe
disease, poor prognosis
- - - - Mehra, et al. 2013 [3]
U11/U12 RNP SNRNP35 SSc Lung fibrosis, gastrointestinal
involvement
- - - - Mimori, 1999 [43]
PDGFR PDGFR SSc Unknown - - - - Svegliati Baroni, et al.
2006 [44]
MMP MMP family dSSc Skin, lung, and vascular fibrosis - - - - Mehra, et al. 2013 [3]
tPA PLAT lSSc PAH - - - - Mehra, et al. 2013 [3]
IFI16 IFI16 lSSc Common in SARDs - - - - Mehra, et al. 2013 [3]
Fibrillin 1 FBN1 dSSc Choctaw and Japanese patients;
absent in Caucasians
- - - - Mehra, et al. 2013 [3]
Vascular Receptors AGTR2, EDN1 SSc TOP1+ patients, renal crisis - - - - Mehra, et al. 2013 [3]
ATF2 ATF2 SSc Longer disease duration,
decreased lung function
- - - - Mehra, et al. 2013 [3]
Data are presented as the average of all peptide hits across each autoantibody group, followed by the frequency of peptide detection within the group. For autoantibodies known to target more than one protein or
subunit, data for a single representative protein are shown, with the specific protein highlighted in bold. Associated proteins indicate specific protein targets identified in this study; among autoantibodies not
identified here, the most common targets are listed. Symbols: -, +, ++, and +++ indicate an average of 0, 1–4, 5–9, and ≥10 peptide hits per group, respectively
SSc systemic sclerosis, lSSc limited cutaneous SSc, dSSc diffuse cutaneous SSc, PAH pulmonary arterial hypertension; ILD interstitial lung disease; CREST CREST syndrome (calcinosis, Raynaud phenomenon, esophageal
dysmotility, sclerodactyly, and telangiectasia); PM/Scl polymyositis/scleroderma, PM/DM polymyositis/dermatomyositis
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helicases proteins, while community 8 contains a diverse
array of proteins including multiple SSc autoantibodies,
including TOP1, SSB, Pm/Scl proteins, URNPs, and
HNRNPs, and numerous serine/arginine-rich splicing
factors. Community 3 consists primarily of aminoacyl
tRNA synthetases, a cluster often targeted in auto-
immune diseases [19, 23]. Communities 4, 5, and 9 are
strongly associated with a variety of GO processes
known to play a major role in SSc, including wound
healing, IFN signaling, and response to oxidative stress.
Major proteins include CD44, HLAs, myosins, and fila-
min proteins in community 4 and tricarboxylic acid
cycle proteins in community 5. Community 9 contains
multiple protein disulfide isomerases and peroxiredox-
ins, protein folding enzymes such as calnexin (CANX)
and calreticulin (CALR), and the major collagen process-
ing enzyme prolyl 4-hydroxylase beta (P4HB). Commu-
nity 6 contains multiple annexin and 14-3-3 proteins;
enriched GO processes include ribonucleoprotein com-
plex assembly, mitochondrial transport, RNA processing,
and anchoring junction. Community 7 associated with
GO terms include cell cycle, RNA polymerase III com-
plex, DNA-PK-Ku complex, and antigen processing and
presentation. Community 7 includes several SSc auto-
antibody targets including Ku proteins XRCC5 and 6,
RUVBL1 and 2, RNA polymerase I and II subunits, mul-
tiple proteasomal subunits, and T-complex proteins.
Preferential detection of autoantibodies in SSc
Subsequent comparisons between groups were performed
in a semiquantitative manner based on the presence or ab-
sence of a given protein in an immunoprecipitant, with
quantitative analyses limited to comparisons within an
individual sample. To identify biological processes and
cellular components differentially targeted in SSc, with
minimal to no background detection in controls, we ex-
amined all proteins detected in >50 % of SSc samples at a
frequency >1.5-fold relative to controls, resulting in a list
of 137 differentially detected proteins (Fig. 2; Additional
file 2: Table S2). Enriched biological processes included
ncRNA metabolic process, response to oxygen radical, and
triglyceride-rich lipoprotein particle remodeling. Preferen-
tially targeted cellular components include cytosolic stress
granule, lipid-protein complex, pigment granule, and an-
choring junction; molecular functions include antioxidant
activity and mRNA binding (Additional file 3: Table S3C).
RNA processing centers are major targets of SSc
autoantibodies
The strong enrichment for GO terms associated with
mRNA processing and stress response, as well as the
identification of cytosolic stress granule as an enriched
cellular component, led us to further investigate the role
of stress granules (SG) and RNA processing bodies (PB)
in the autoantibody response of SSc. SG and PB repre-
sent distinct, non-membranous cytoplasmic entities,
which arise in response to different cellular stresses
including oxidative stress, hypoxia, viral infection, un-
folded proteins, and amino acid deprivation [24].
These structures exist in constant flux, driven by the
availability of constituent mRNPs, regulating the fate
of untranslated mRNAs in response to translational
arrest [25]. While SG are generally absent under nor-
mal conditions, PB are constitutively present at low
levels due to their role as microRNA processing cen-
ters. Both structures have been shown to arise in re-
sponse to cellular stresses, including oxidative stress,
ischemia, and cancer [26], all of which are known to
be important in SSc pathogenesis [5, 27].
In addition to the 137 differentially detected proteins de-
scribed above, a wide range of PB/SG constituents were
readily detected across most SSc samples (Additional file 5:
Table S4). Substantial reactivity was seen against PB com-
ponents such as UPF1 and MOV10, and SG proteins FXR1
and FXR2, G3BP1 and G3BP2, and USP10. Only back-
ground levels of reactivity were seen in healthy controls.
Validation of PB/SG antibodies in SSc
In order to validate the differential abundance of PB/SG
proteins identified by LC-MS/MS, HeLa whole cell ly-
sates were immunoprecipitated using antibodies from
each patient as described in the LC-MS/MS analyses.
Western blots were performed by resolving equal vol-
umes of IP eluates by SDS-PAGE and transferring to
nitrocellulose. Blots were then probed with antibodies
targeting PB/SG proteins UPF1, MOV10, CAPRIN1,
G3BP1, and USP10. These targets were chosen based
upon their high level of detection across SSc groups, as
determined based on our LC-MS/MS data. Strong re-
activity was seen against all five proteins in SSc with
only trace levels detected in controls (Fig. 3a), indicating
widespread immune responses against these protein
complexes.
Further validation was performed using immunofluor-
escence (IF) staining of U2OS cells maintained under
conditions of oxidative stress to induce PB/SG forma-
tion. Cells were probed with patient sera in combination
with PB and SG markers SK1-Hedls and eIF3b, respect-
ively. Co-localization between patient sera and PB/SG
markers was observed in six of nine SSc patients, with at
least one positive sample in each of the three autoanti-
body groups; no staining was seen for any of the three
healthy controls (Fig. 3b). These results are consistent
with that seen on LC-MS/MS, particularly among
RNAP3 patients, who exhibited the strongest and most
consistent autoantibody responses across both methods.
Taken together, these data strongly implicate PB/SG as
novel targets of SSc autoantibody responses.
Johnson et al. Arthritis Research & Therapy  (2016) 18:27 Page 8 of 13
Discussion
Autoantibodies have long been used in the diagnosis of
SSc, with different autoantibodies predictive of clinical
outcomes, including interstitial lung disease, pulmonary
arterial hypertension, and skin involvement. While a
wide array of SSc-associated autoantibodies have been
described, diagnoses are often performed based upon
the presence or absence of reactivity against three pro-
teins: RNAP3, TOP1, and CENP. The data presented
here suggest a much broader autoantibody response,
which is reflective of underlying disease pathologies.
Strong subset-specific reactivity was evident against both
RNAP3 and TOP1, with no RNAP3 peptides detected in
any of the other groups; however, all four RNAP3 pa-
tients exhibited modest reactivity against TOP1, indicat-
ing a degree of overlap between these two autoantibody
groups. When peptides recovered are extended beyond
the three major targets, we found substantial overlap
across the three major SSc groups. We found peptides
from the autoantigens of RuvBL1/2, which appear to act
as general markers of SSc, with consistent detection
across all SSc groups, with almost no reactivity seen in
controls. In contrast, some common SSc autoantigens
such as B23 and Ro52/TRIM21 were recovered in virtu-
ally all samples, and in controls, indicating an important
degree of baseline reactivity against some of the more
common autoantibody targets.
In this proof-of-concept study, we do not attempt to
address the clinical implications of the autoantibody re-
sponses described here due to the limited number of pa-
tients analyzed, nor are we able to speculate on the
presence or absence of these autoantibodies in other SSc
autoantibody groups. Our depth in this study comes from
the number of potential antigens analyzed, which cover
the full proteome. Future studies examining a much larger
cohort of SSc patients, along with representatives of other
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autoimmune diseases, will be necessary to determine the
clinical value of these potential autoantibodies.
This is not the first study to suggest the presence of
multiple autoantibodies in SSc. Immunoassays per-
formed by Op De Beeck, et al. revealed the presence of
multiple autoantibodies in a small subset of SSc patients
[28]. A similar analysis by Graf et al. using the EURO-
LINE immunoassay revealed the presence of multiple
autoantibodies in 11 % of patients [1].
Autoantibodies against extracellular immune signaling
receptors and extracellular matrix proteins were con-
spicuously absent in these data; this includes the absence
of numerous autoantibodies previously implicated in SSc
pathogenesis, such as anti-fibrillin 1, anti-MMP, and
anti-PDGFR [29]. Additional analyses in other cell types,
such as fibroblasts or endothelial cells, and cells main-
tained under physiologically relevant growth conditions,
such as immune activation or oxidative stress, may be
useful for identifying other proteins and complexes
which may play a role in disease pathogenesis.
In addition to identifying novel autoantibody targets,
the unbiased nature of mass spectrometry provides add-
itional insights into the processes potentially underlying
autoimmunity. The preferential detection of proteins as-
sociated with RNA processing and oxidative stress as a
general feature of SSc autoantibodies may be indicative
of their origins. Combined with the consistent targeting
of PB/SG described here spanning all SSc patients, these
data suggest a basic model in which disease-specific
pathologies give rise to specific autoantibodies. Strong
induction of SGs is observed in response to cellular
stresses, including oxidative stress and ischemia, two
well-established phenomena in SSc [27]. SG/PB are also
readily induced in response to the tumor microenviron-
ment, consistent with recent evidence linking RNAP3-
positive SSc and cancer [5, 30]. Combined with evidence
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Fig. 3 Validation of RNA processing bodies (PB)/stress granules (SG) as a target of the SSc autoimmune response. a HeLa cell lysates
were immunoprecipitated using patient sera, resolved by SDS-PAGE, and probed with antibodies targeting known PB and SG proteins;
HeLa whole cell lysate was used as a control. b Immunofluorescence was performed in U2OS cells treated with sodium (meta)arsenite
to induce the formation of SG. Cells were then fixed with 4 % paraformaldehyde and permeabilized with 5 % normal horse serum
and 0.1 % digitonin in Tris-buffered saline. Staining was performed with anti-eIF3b (SG marker), anti-SK1-Hedls (PB marker), and patient
sera. Representative images depicting co-localization between patient sera and SG/PB markers are shown, with sites of co-localization
circled in red. RNAP RNA polymerase, CENP centromere protein TOPI topoisomerase I
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linking transforming growth factor (TGF)-β signaling
with an increase in PB formation [31], many of the
major processes underlying SSc pathogenesis appear
broadly consistent with an immune response against
cells undergoing a stress response. PBs are also known
to associate with other cytoplasmic structures, such as U
bodies [32], which house an number of well-established
SSc autoantibody targets, including U1, U5, and U11/U12.
Taken together, these data suggest a model in which auto-
antibodies arise as a secondary phenotype in response to
SSc-related processes already underway.
Some evidence suggesting a link between PBs and
autoimmunity has been described previously. Bhanji, et
al. observed reactivity against a number of PB-associated
proteins, including GE1/Hedls, GW182, and Ago2 in a
range of autoimmune diseases, including SSc [33]. Among
these autoantigens, only Ago2 was also identified in this
analysis, suggesting a persistent, yet diverse response
against this complex. A similar analysis of SG-associated
proteins has not been performed; however given the re-
activity to PB proteins seen in other autoimmune diseases,
reactivity in other autoimmune diseases is possible. A de-
tailed analysis using both mass spectrometry and other
methods will be necessary to understand the degree to
which autoantibodies to SG/PBs are seen in other auto-
immune diseases, and the clinical implications of these
findings.
This work has several limitations. First, we cannot
eliminate the possibility that some proteins found in our
mass spectrometry data result from co-IP of multi-
protein complexes by a single autoantibody; however, we
were able to confirm the presence of multiple PB/SG
autoantibodies by other means (Fig. 3). We also cannot
rule out the possibility that some targets were missed
due to their being sequestered into tightly packed
molecular complexes associated with chromatin. For
example, the presence of CENP autoantibodies within
these samples had been established using clinical methods,
indicating its absence in our mass spectrometry data is
likely a result of its sequestration into large macromolecu-
lar complexes with limited solubility. A lack of age- and
gender-matched controls likely underestimates the degree
of baseline reactivity seen in unaffected controls. Finally,
the small number of patient samples used in this study
prevents any clinical interpretation, and the variability in
the number of peptides recovered between experiments
limits direct quantitative comparisons between autoanti-
body groups.
Conclusions
The data presented here provide evidence of diverse im-
mune reactivities in SSc targeting a wide array of protein
complexes. Among these complexes, autoantibodies tar-
geting PB/SG were consistently identified across both
clinical SSc subsets and major autoantibody groups, sug-
gesting a potential novel autoantibody target. Taken to-
gether, these data suggest immune responses to proteins
involved in cellular stress may be a common mechanism
for autoantibody generation.
Additional files
Additional file 1: Table S1. Complete list of peptides identified in this
analysis. TP number of total peptides mapping to a protein, UP number
of unique peptides mapping to a protein, UM number of non-redundant
peptides mapping exclusively to a protein, MW molecular weight, Length
protein length in amino acids. (XLS 639 kb)
Additional file 2: Table S2. Gene lists used in these analyses.
(XLSX 17 kb)
Additional file 3: Table S3. Systemic sclerosis (SSc)-specific enrichment
of processes and components. Proteins differentially detected in SSc
were analyzed using gProfiler. Statistically significant processes and
components are shown. A) Peptides detected at any level across all
four groups. B) Peptides identified in all SSc groups, but absent in
controls. C) Analysis of 137 proteins differentially detected in SSc. BP
biological process, CC cellular component, MF molecular function, ke
KEGG pathway, re REACTOME pathway. (ODS 70 kb)
Additional file 4: Figure S1. Network analysis of systemic sclerosis
(SSc) autoantigens. All 763 non-redundant peptide hits identified in two
or more patients were analyzed using the Genome-scale Integrated
Analysis of gene Networks in Tissues (GIANT) global network to identify
functionally associated protein networks. Analysis of community function
was performed using gProfiler. SSc-associated autoantibodies are highlighted
in yellow. (EPS 1902 kb)
Additional file 5: Table S4. Processing body and stress granule
proteins identified in this analysis. *Proteins with multiple subunits. Data
indicate non-redundant peptide hits. (ODS 20 kb)
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